In this episode of Mayo Clinic Laboratories’ “Leveraging the Laboratory” podcast, host Jane Hermansen, outreach manager at Mayo Clinic Laboratories, is joined by colleagues Ellen Dijkman Dulkes and Brianne Newton. They discuss common challenges outreach programs face that can lead to a program’s failure and how to overcome those barriers.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss the value laboratories deliver for their entire health system.

Learn the five elements essential to successfully implementing a complex outreach program project and what is at risk if you miss an element.

In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, is joined by Russ Lebovitz, M.D., Ph.D., CEO and co-founder of Amprion. They discuss their strategic collaboration and the innovative SAAmplify™–αSYN (CSF) test.

In the first quarter of 2025, Mayo Clinic Laboratories expanded its test catalog with several innovative new tests.

Medical Laboratory Professionals Week is a time to appreciate the profound impact of laboratory medicine on healthcare and innovation.

Communication is a critical component of success. Laboratory outreach leaders can foster truly effective communication with five simple steps.

Learn why threshold diagnoses of the breast are important, how to approach them, and what role technology might play in the future.

PACE / State of FLRegister now - June 12, 2025: This webinar will review important considerations when it comes to negotiating, maintaining and monitoring payer agreements, as well as cover basic terminology and nuances related to network benefits design.

Paul Jannetto, Ph.D., explains how Mayo Clinic Laboratories' SPAS test identifies the form of arsenic present in patients with arsenic exposure. That information is important for determining the potential level of harm and for removing the patient from the arsenic source to ease symptoms and prevent cancer risk.

By using a test that measures neurofilament light chain (Nfl) proteins in blood, clinicians can better diagnose devastating diseases like ALS and MS, help predict disease progression, and better assess efficacy of existing drugs and trial therapies.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss the recent court judgment on the U.S. Food and Drug Administration’s (FDA) oversight of lab-developed tests (LDT).

PACE / State of FL - Presentation Recording Coming Soon - This webinar will explore the role of cytology specimens in molecular genetic testing, emphasizing their effectiveness in identifying biomarkers critical for targeted therapies in patients with cancer. Advantages of cytology samples, challenges in specimen adequacy, and how advancements in next-generation sequencing (NGS) have led to improved utilization of cytology samples will be discussed. This discovery has led to enhancing diagnostic accuracy, reducing the need for repeat biopsies, and accelerating personalized cancer treatment, all of which will be highlighted during the webinar.

Jessica Wright, Pharm.D., BCACP, explains how Mayo Clinic Laboratories' 3A5Q test helps determine initial tacrolimus doses for individuals after non-liver organ transplants. Optimal tacrolimus levels are one of the important factors in survival of the transplanted organ.

In this microlearning, we'll explore the importance of human connection in our daily lives and how the sense of belonging is a fundamental part of being human. As technology evolves, it reshapes how we interact with one another, creating new ways to connect and communicate, even in the realm of human relationships.